---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029165"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:25:22.710335+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data

## Summary
- Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.
- Net loss $69.0M for FY2024 ($20.2M Q4), vs $58.3M prior year; R&D spend $68.4M.
- JANX007 PSMA-TRACTr Phase 1: 100% PSA50, 63% PSA90, 50% ORR (4/8), well-tolerated safety; data cutoff Nov 15, 2024.
- JANX008 EGFR TRACTr Phase 1 enrollment ongoing; data update and R&D Day planned for 2025.
- Zachariah McIver promoted to Chief Medical Officer; he previously served as Amgen's Executive Medical Director.

## SEC filing metadata
- accession: 0000950170-25-029165
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017025029165/0000950170-25-029165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017025029165/janx-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029165
- JSON: https://secwatch.observer/filing/0000950170-25-029165.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.